Windlas Biotech enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


1,876	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
269	269	224	179	110
29.9	29.9	27.1	0.1	0.4
1,637	—	—	—	—
−239	−239	−197	−179	−110
₹775.45	—	—	—	—

611	611	533	450	403
4.9%	4.9%	5.1%	0.0%	0.1%
0.02×	—	—	—	—

1.74×	—	—	—	—
15.61×	—	—	—	—
22.01×	—	—	—	—
43.92×	—	—	—	—
942	904	760	631	513
105	105	94.1	78.1	60.2
74.3	74.0	66.1	64.7	47.9
—	105	68.2	109	61.0
37.3	37.3	16.0	71.2	−9.9
—	36.1	15.0	71.0	−10.1
—	67.7	52.2	37.7	70.9

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

WINDLAS₹888.70

Windlas Biotech Limited

· Pharma & Health

₹ CrorePeersHESTERBIO INDOCO SAIPARENT SYNCOMF PANACEABIO NGLFINE HIKAL JAGSNPHARMMcap ₹1,876 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	1,875.7
- Cash, Equiv & ST Investments	110.2	178.7	223.8	268.9	268.9
+ Total Debt	0.4	0.1	27.1	29.9	29.9
Enterprise Value	—	—	—	—	1,636.7
Net Debt (memo)	-109.8	-178.6	-196.7	-239.0	-239.0
EV per Share	—	—	—	—	775.45

Total Capital	403.1	450.4	532.9	610.7	610.7
Total Debt/Total Capital	0.11	0.02	5.09	4.89	4.89
Total Debt/EV	—	—	—	—	0.02

EV/Sales	—	—	—	—	1.74
EV/EBITDA	—	—	—	—	15.61
EV/EBIT	—	—	—	—	22.01
EV/Free Cash Flow	—	—	—	—	43.92
Reference Items — Trailing FY Values
Sales	513.1	631.0	759.9	904.1	942.1
EBITDA	60.2	78.1	94.1	104.7	104.9
EBIT	47.9	64.7	66.1	74.0	74.3
Operating Cash Flow	61.0	108.9	68.2	104.9	—
Free Cash Flow	-9.9	71.2	16.0	37.3	37.3
FCFF (free cash flow to the firm)	-10.1	71.0	15.0	36.1	—
Capital Expenditure	70.9	37.7	52.2	67.7	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.